NCI issues omics checklist for tests.
The National Cancer Institute has released a 30-item checklist to evaluate the readiness of complex omics-based tests used to guide therapeutic choices for patients in a clinical trial. The checklist pertains to tests that combine multiple molecular measures from genomic, proteomic, metabolomic, transcriptomic, epigenomic, or other omics assays into predictive mathematical models. The agency will approve tests for use in a trial only if all 30 criteria have been adequately addressed.